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A b s t r a c t 
Introduction: Obesity and inadequate vitamin D status are associated with 
endothelial dysfunction and cardiovascular disease. We evaluated the asso-
ciations between vitamin D status (i.e. serum levels of 25-hydroxyvitamin D 
(25(OH)D)), biomarkers of endothelial dysfunction (i.e. serum concentra-
tions of soluble intercellular adhesion molecule 1 (sICAM-1) and soluble 
E-selectin (sE-selectin)), inflammatory markers (i.e. high-sensitivity C-reac-
tive protein (hsCRP) and fibrinogen) and cardiometabolic risk factors. 
Material and methods: Fifty obese (body mass index (BMI) ≥ 30 kg/m2) 
non-diabetic adults (mean age: 36.2 ±5.4 years) without pre-existing car-
diovascular abnormalities and 25 clinically healthy, normal weight and age-
matched individuals were included. Anthropometric parameters, markers of 
glucose and lipid metabolism, and serum levels of inflammatory and endo-
thelial dysfunction biomarkers were assessed in all subjects.
Results: The mean serum 25(OH)D level was significantly lower in the obese 
group than in controls (33.5 ±15.2 vs. 60.1 ±23.1 nmol/l; p < 0.001). In the 
obese group, sE-selectin (36.4 (32.1–47.2) vs. 32.4 (24.6–35.5) ng/ml, p < 0.05) 
and hsCRP (6.0 ±3.4 vs. 3.5 ±1.0 mg/l, p < 0.05) were significantly higher in 
individuals with lower than median vitamin D levels (i.e. 31 nmol/l) compared 
with those with higher vitamin D levels. In multivariable linear regression 
analysis, hsCRP (β = –0.43; p < 0.001) and sE-selectin (β = –0.30; p = 0.03) 
were independently and significantly associated with serum 25(OH)D levels 
in the obese group.
Conclusions: Vitamin D levels may be related to increased levels of bio-
markers of endothelial dysfunction and inflammation in obese non-diabetic 
individuals.
Key words: vitamin D, endothelial dysfunction, inflammation, obesity, 
cardiometabolic risk factors.
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Introduction
Excessive food intake, genetic predisposition and 
lack of physical activity are the main causes of obe-
sity [1]. Visceral depots contribute to a  low-grade, 
chronic inflammatory status, involved in the patho-
genesis of insulin resistance and obesity-related 
diseases such as type 2 diabetes mellitus (T2DM) 
and cardiovascular disease (CVD) [2, 3]. This chron-
ic inflammation includes phenotypic conversion 
of endothelial cells (ECs) into an active form with 
consequent interactions with circulating leukocytes 
[4]. Leukocyte-endothelium interactions (rolling, ad-
herence and extravasation) are mediated by cell ad-
hesion molecules expressed on the endothelial cell 
surface such as the selectin family of adhesion mol-
ecules including E-selectin and the immunoglobulin 
family of adhesion molecules including intercellular 
adhesion molecule 1 (ICAM-1) [1, 4]. The prolonged 
exposure of vascular endothelium to cardiometa-
bolic risk factors may lead to continuous endothelial 
activation and dysfunction [5–10]. In this context, 
the clinical manifestation of the endothelial pheno-
type depends on the balance between exposure to 
risk factors and endothelial repair [6].
Vitamin D has a potential protective effect on 
the vascular endothelium [11]. Endothelial cells 
express Vitamin D receptors and 1α-hydroxylase 
activity, thus allowing autocrine production of 
1,25-dihydroxyvitamin D (1,25(OH)D2), the bio-
logically active form of vitamin D [12, 13]. Apart 
from the capacity to modulate the effects of proin-
flammatory cytokines on the vascular endotheli-
um and to decrease the expression of endotheli-
al adhesion molecules, vitamin D may also exert 
antioxidant properties, and it may be involved in 
repairing damaged ECs [14]. In clinical studies, it 
has been proposed that vitamin D deficiency and/
or insufficiency is associated with impaired endo-
thelial function [6]. Furthermore, several studies 
have shown an inverse correlation between se-
rum 25-hydroxyvitamin D (25(OH)D) levels and 
biomarkers of endothelial dysfunction in patients 
with hypertension, T2DM, coronary artery disease 
and stroke [15–17]. Vitamin D insufficiency is more 
prevalent in obese individuals [18–20]. Moreover, 
cross-sectional studies have reported inverse as-
sociations between low serum 25(OH)D levels and 
cardiometabolic risk factors (e.g. abdominal obe-
sity, hypertension, hyperglycemia) [21, 22], which 
may also promote the development and progres-
sion of endothelial dysfunction in obese patients. 
The main objective of this study was to deter-
mine the associations between vitamin D status 
(represented by serum 25(OH)D levels) and cir-
culating biomarkers of endothelial dysfunction 
(serum concentration of soluble forms of endo-
thelium-derived adhesion molecules, i.e. sICAM-1 
and sE-selectin), inflammation (high-sensitivity 
C-reactive protein (hsCRP) and fibrinogen) and car-
diometabolic risk factors (parameters of glucose 
and lipid metabolism) in obese non-diabetic mid-
dle-aged adults in the absence of pre-existing CVD. 
Material and methods
Subjects
This cross-sectional pilot study was performed 
during 6 months (May to October 2012), at the 
Department of Endocrinology, Diabetes and Meta-
bolic Disorders, Clinical Center of Vojvodina (CCV). 
We evaluated 50 (34 female) obese patients (body 
mass index (BMI) > 30 kg/m2) with no pre-existing 
CVD, hypertension (systolic blood pressure (SBP) 
≤ 130 mm Hg, diastolic blood pressure (DBP) ≤ 
80 mm Hg) or T2DM (2 repeated measurements 
of fasting glucose levels < 7 mmol/l and glycated 
hemoglobin A
1c (HbA1c) < 6.5%). Patients with he-
patic, psychiatric or malignant disorders were ex-
cluded from the study. The control group consisted 
of 25 participants (20 female) with normal weight 
(BMI < 25 kg/m2), clinically healthy and matched 
for age with the obese group. We also excluded 
smokers, subjects in acute stress situations or with 
infections (hsCRP > 10 mg/l), as well as those with 
recent (i.e. 3 months) weight changes, calcium 
level disturbances or treated with calcium or Vi-
tamin D supplements 3 months prior to the study. 
Obese patients (n = 50) were classified into 
2 subgroups according to the median serum 
25(OH)D levels for this group (i.e. 31 nmol/l).
The study was conducted according to the Dec-
laration of Helsinki and approved by the Ethical 
Committees of CCV. Informed consent was ob-
tained from every participant.
Study protocol 
All participants attended the CCV outpatient 
clinic for anthropometric measurements and clin-
ical examination; 24  h before blood sampling, 
participants were asked to refrain from strenuous 
physical activity and consuming alcoholic beverag-
es or caffeine. Venous blood was drawn from an 
antecubital vein after a 12 h overnight fast. Analy-
ses were performed immediately after sampling ex-
cept for serum sICAM-1 and sE-selectin. They were 
centrifuged 15 min at 1000×g, and stored at –70°C 
for 1 month. Blood glucose and insulin levels were 
measured before (fasting plasma glucose (FPG) and 
fasting plasma insulin (FPI)) and 2 h after the inges-
tion of a 75 g oral glucose load (2 h plasma glucose 
(2hPG) and 2 h plasma insulin (2hPI)).
Anthropometric and clinical measurements
Body weight (BW, kg), fat adipose tissue per-
centage (FAT%) and trunk fat mass percentage 
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(FAT trunk %) were determined by the bioelec-
trical impedance method (Tanita TBF-310 Body 
Composition Analyzer; Tanita Corporation, Tokyo, 
Japan). Body height (BH, m) was measured using 
a  Harpenden anthropometer (Holtain Ltd, Cros-
well, UK). Body mass index was calculated as BW/
BH2 (kg/m2). WC was measured using a  tape to 
0.1 cm. Blood pressure was measured according 
to a  standard protocol (Riva Rocci method, mer-
cury sphygmomanometer), in the sitting position 
after a 10 min rest.
Analytical procedures 
Standard methods were used to assess blood 
glucose levels (hexokinase method), insulin levels 
(chemiluminescent immunoassay, Siemens Ad-
via Centaur XP), HbA1c (immuno-inhibitory test), 
hsCRP levels (Olympus AU 400, Beckman-Coulter, 
Ireland), fibrinogen (ACL system, Instrumentation 
Laboratory, Italy) and lipids (Olympus AU 400, 
Beckman-Coulter, Ireland). Serum 25(OH)D con-
centrations were measured by the electrochemi-
luminescence immunoassay using an automated 
clinical chemistry analyzer (Elecsys 2010, Roche 
Diagnostics); sICAM-1 and sE-selectin levels were 
measured by the Quantikine Human sICAM-1 im-
munoassay and Quantikine Human sE-Selectin 
immunoassay, ELISA, respectively (R&D Systems, 
Minneapolis, USA), according to the manufactur-
ers’ instructions.
Insulin resistance was defined as HOMA-IR ≥ 
2.5 [23]. Hypertriglyceridemia (i.e. triglycerides 
(TG) ≥ 1.7 mmol/l), low high-density lipoprotein 
cholesterol (HDL-C) (i.e. HDL-C ≤ 1.0 mmol/l in 
men and ≤ 1.3 mmol/l in women) and central obe-
sity (i.e. WC ≥ 102 cm in men and ≥ 88 cm in wom-
en) were recorded for each patient [24].
Statistical analysis
Normal distribution of continuous variables 
was assessed with the Shapiro-Wilk test. Data 
were presented as mean ± standard deviation 
for normally distributed continuous variables and 
median (interquartile range) for non-parametric 
continuous variables, while categorical data were 
presented as percentages. Parametric (t-test) and 
non-parametric (Mann-Whitney) statistical tests 
were used. The c2 test was used for categorical 
variables. Correlations between 25(OH)D levels 
and other variables were evaluated by Pearson 
or Spearman coefficients. All correlations were 
weighted by BMI. Further, we performed a multi-
variate regression analysis to assess the associ-
ations between serum 25(OH)D levels, biomark-
ers of inflammation and endothelial dysfunction. 
Regression analysis was adjusted for BMI by add-
ing it to the regression model. Statistical analysis 
was performed using MedCalc 12.1.4.0 statistical 
software (MedCalc Software, Mariakerke, Bel-
gium). Differences were considered significant if 
p (2-tailed) < 0.05.
Results
Comparisons of anthropometric characteristics, 
biochemical measurements and biomarkers of in-
flammation and endothelial dysfunction between 
groups are shown in Table I. Significant differenc-
es between the obese and control group were ob-
served in all studied variables except for DBP, FPG 
and 2hPG. The mean serum 25(OH)D level was 
significantly lower in the obese group than in con-
trols (33.5 ±15.2 vs. 60.1 ±23.1 nmol/l; p < 0.001).
Regarding HOMA-IR, the prevalence of insulin 
resistance among obese subjects was 78%. The 
prevalence of hypertriglyceridemia (4% vs. 36%, 
p = 0.03) and low HDL-C levels (8% vs. 41%, p = 
0.04) was significantly lower in controls compared 
with the obese group.
In the obese group (Table II), BMI, 2hPG, hsCRP 
and sE-selectin levels were significantly high-
er in those patients with 25(OH)D < 31 nmol/l 
compared with those with 25(OH)D ≥ 31 nmol/l 
(p < 0.05 for all comparisons). The prevalence of 
insulin resistance (72% vs. 60%, p = 0.85), hyper-
triglyceridemia (32% vs. 40%, p = 0.89) and low 
HDL-C levels (56% vs. 41%, p = 0.93) did not differ 
significantly between the 2 subgroups of obese 
patients.
Correlation analysis showed significant neg-
ative correlations between serum 25(OH)D lev-
els and BMI (r = –0.33, p = 0.02), WC (r = –0.25, 
p = 0.03), FAT trunk % (r = –0.19, p = 0.03), sE-se-
lectin (r = –0.41, p = 0.01), sICAM-1 (r = –0.30, 
p = 0.02), hsCRP (r = –0.46, p = 0.01) and HOMA-IR 
(r = –0.29, p = 0.03) in all (obese and control sub-
jects) patients. There were no significant correla-
tions between serum 25(OH)D levels, fibrinogen 
and lipid parameters. 
In linear regression analysis serum 25(OH)D 
levels were significantly associated with hsCRP 
(β = –0.49; p = 0.00), sE-selectin (β = –0.32; p = 
0.03), sICAM (β = –0.12; p = 0.04) and BMI (β = 
–0.25; p = 0.02) in the obese group. In contrast, 
the association between serum 25(OH) level and 
HOMA-IR was insignificant among obese patients. 
In obese patients, the association between se-
rum 25(OH)D levels and biomarkers, hsCRP (β = 
–0.43; p = 0.00) and sE-selectin (β = –0.30; p = 
0.03) was confirmed in a multivariable (stepwise) 
linear regression analysis (R2 = 0.40, R2 adjusted = 
0.38) after including BMI (p = 0.02) in the analysis. 
Accordingly, per unit increase in serum 25(OH)D 
(nmol/l) levels we observed a corresponding sig-
nificant reduction of hsCRP (0.43 mg/l) and sE-se-
lectin (0.30 ng/ml).
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Discussion
The vascular endothelium is an important 
source of circulating soluble adhesion molecules 
[25, 26]. Elevated levels of these markers reflect 
endothelial dysfunction and can be used as surro-
gates for increased CVD risk [27]. Previous studies 
suggest that vitamin D deficiency is associated 
with a proinflammatory state in obesity [28, 29], 
but there are still confounding data with regard to 
the associations of vitamin D levels and certain 
biomarkers of endothelial dysfunction in obese 
non-diabetic patients without pre-existing CVD. 
Vitamin D insufficiency may also be associated 
with the metabolic syndrome [30].
In the present study, obese non-diabetic indi-
viduals had significantly lower serum 25(OH)D 
levels compared with normal weight controls as 
well as significantly increased sICAM-1, sE-selectin, 
hsCRP and fibrinogen levels. Furthermore, BMI, 
2hPG, hsCRP and sE-selectin levels were signifi-
cantly higher in the obese patients with 25(OH)D 
< 31 nmol/l than in those with 25(OH)D ≥ 31 nmol/l. 
Insulin resistance was frequent in the obese 
group (i.e. 78%). The prevalence of hypertriglycer-
idemia and low HDL-C levels was significantly 
higher in obese patients compared with controls. 
In contrast, the frequency of these metabolic dis-
orders did not significantly differ between the 
2 obese subgroups according to 25(OH)D levels 
(i.e. < or ≥ 31 nmol/l).
Obesity markers are important independent 
predictors of CV risk [3]. We found that BMI, but 
not WC, was significantly higher in obese patients 
with 25(OH)D levels < 31 nmol/l than in those 
obese with 25(OH)D ≥ 31 nmol/l. Although BMI, 
WC and FAT trunk % had a significant and inverse 
correlation with vitamin D levels in all studied sub-
Table I. Study population characteristics
Parameter Obese (n = 50) Control (n = 25) P-value
Age [years] 36.2 ±5.4 34.3 ±3.6 0.09
Gender (m/f) 16/34 13/12 0.15
BMI [kg/m2] 40.8 ±8.5 22.8 ±2.3 < 0.001
WC [cm] 127.6 ±19.2 82.0 ±9.3 < 0.001
FAT trunk (%) 38.6 ±7.6 18.9 ±6.2 < 0.001
SBP [mm Hg] 123 ±9 114 ±9 < 0.001
DBP [mm Hg] 81 ±5 79 ±4 0.79
FPG [mmol/l] 5.0 ±1.2 4.7 ±0.4 0.41
2hPG [mmol/l] 5.7 ±1.9 5.0 ±1.1 0.21
FPI [mU/ml] 18.3 ±11.8 6.8 ±4.4 < 0.001
2hPI [mU/ml] 44.7 ±34.1 20.8 ±21.4 < 0.001
HOMA-IR 4.2 ±2.9 1.5 ±1.0 < 0.001
HbA1c [mmol/l] 35.3 ±5.6 31.2 ±1.9 < 0.001
LDL-C [mmol/l] 3.7 ±0.9 2.7 ±0.4 0.0001
HDL-C [mmol/l] 1.1 ±0.3 1.4 ±0.3 < 0.001
TG [mmol/l] 1.37 (1.08–1.77) 0.82 (0.59–1.04) 0.0005
hsCRP [mg/l] 5.1 (2.92–6.27) 0.2 (0.1–0.8) < 0.001
Fibrinogen [g/l] 3.6 ±0.8 2.5 ±0.5 < 0.001
sE-selectin [ng/ml] 36 (29–44) 26 (23–31) < 0.001
sICAM-1 [ng/ml] 263 (229–332) 185 (166–208) < 0.001
25(OH)D [nmol/l] 33.5 ±15.2 60.1 ±23.1 < 0.001
Continuous variables are expressed as means ± SD or median (interquartile range) and categorical data as percentages (%). 
25(OH)D – 25-hydroxyvitamin D, BMI – body mass index, WC – waist circumference, FAT trunk % – trunk fat mass percentage, SBP – systolic 
blood pressure, DBP – diastolic blood pressure, FPG – fasting plasma glucose, 2hPG – 2 h plasma glucose, FPI – fasting plasma insulin, 
2hPI – 2h plasma insulin, HOMA-IR – homeostasis model assessment of insulin resistance, HbA
1c
 – glycated hemoglobin, LDL-C – low-
density lipoprotein cholesterol, HDL-C – high-density lipoprotein cholesterol, TG – triglycerides, hsCRP – high-sensitivity C reactive protein, 
sE-selectin – soluble E-selectin, sICAM-1 – soluble intercellular adhesion molecule-1.
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jects, only BMI was significantly associated with 
25(OH)D levels in obese patients. This finding is 
consistent with previous studies suggesting that 
an increase in BMI may decrease vitamin D levels 
in obese patients, and different mechanisms have 
been proposed to explain the relationship between 
obesity and low vitamin D status [18, 19, 21].
As previously shown, obese patients have el-
evated levels of soluble adhesion molecules in 
the presence of CV risk factors (e.g. insulin resis-
tance, atherogenic dyslipidemia, hypertension, 
inflammation) [5, 9, 10, 26]. Considering the role 
of adhesions molecules in vascular inflammation 
and atherosclerosis, it has been suggested that 
levels of their soluble form may be a predictor of 
atherosclerotic CVD in apparently healthy men 
and women [31]. Additionally, a recent study sug-
gested that an increase in serum level of the sol-
uble form of endothelial cell-derived chemokines 
(CXCL16) could be associated with the presence of 
atherosclerotic cerebrovascular disease (ischemic 
stroke) [32].
Table II. Characteristics of the obese subjects according to median serum 25(OH)D levels (i.e. 31 nmol/l)
Parameter Obese with 25(OH)D 
< 31 nmol/l
(n = 25)
Obese with 25(OH)D 
≥ 31 nmol/l
(n = 25)
P-value
Age [years] 37.2 ±4.9 36.7 ±4.8 0.54
Gender (m/f) 18/7 13/12 0.24
BMI [kg/m2] 43.2 ±10.2 37.5 ±4.9 0.03
WC [cm] 129.1 ±21.5 126.8 ±12.4 0.12
FAT trunk (%) 41.9 ±6.2 40.4 ±4.9 0.19
SBP [mm Hg] 126 ±10 125 ±7 0.26
DBP [mm Hg] 80 ±2 78 ±5 0.68
FPG [mmol/l] 5.0 ±1.0 4.7 ±0.6 0.16
2hPG [mmol/l] 5.5 ±2.0 5.0 ±1.3 0.02
FPI [mU/ml] 14.6 (11.2–23.4) 17.4 (13.2–24.6) 0.24
2hPI [mU/ml] 30.2 (22.8–68.4) 25.4 (20.8–65.9) 0.19
HOMA-IR 4.3 ±3.0 4.0 ±2.2 0.21
Prevalence of insulin resistance (%) 72 60 0.85
HbA1c (%) 5.7 ±0.8 5.5 ±0.4 0.74
LDL-C [mmol/l] 3.6 ±0.9 3.5 ±0.7 0.36
HDL-C [mmol/l] 1.0 ±0.2 1.2 ±0.4 0.14
Prevalence of hypo-HDL cholesterol (%) 56 48 0.93
TG [mmol/l] 1.3 (0.7–1.9) 1.4 (1.0–1.9) 0.51
Prevalence of hypertriglyceridemia (%) 32 40 0.89
hsCRP [mg/l] 6.0 ±3.4 3.5 ±1.0 0.02
Fibrinogen [g/l] 3.9 ±0.7 3.3 ±1.0 0.62
sE-selectin [ng/ml] 36 (32–47) 32 (25–35) 0.04
sICAM-1 [ng/ml] 297 (239–340) 259 (223–326) 0.71
25(OH)D [nmol/l] 20.2 ±6.5 50.2 ±14.3 0.001
Continuous variables are expressed as means ± SD or median (interquartile range) and categorical data as percentages (%). 25(OH)D 
– 25-hydroxyvitamin D, BMI – body mass index, WC – waist circumference, FAT trunk % – trunk fat mass percentage, SBP – systolic 
blood pressure, DBP – diastolic blood pressure, FPG – fasting plasma glucose, 2hPG – 2h plasma glucose, FPI – fasting plasma insulin, 
2hPI – 2h plasma insulin, HOMA-IR – homeostasis model assessment of insulin resistance, HbA
1c
 – glycated hemoglobin, LDL-C – low-
density lipoprotein cholesterol, HDL-C – high-density lipoprotein cholesterol, TG – triglycerides, hsCRP – high-sensitivity C reactive protein, 
sE-selectin – soluble E selectin, sICAM-1 – soluble intercellular adhesion molecule-1. Insulin resistance was defined as HOMA IR ≥ 2.5. 
Hypertriglyceridemia was defined as TG ≥ 1.7 mmol/l. Hypo-HDL cholesterol was defined as HDL-C ≤ 1.0 mmol/l in men and ≤ 1.3 mmol/l 
in women.
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In the present study, obese subjects with a low-
er 25(OH)D level (< 31 mmol/l) had significantly 
higher sE-selectin levels. Although recent studies 
suggest that serum 25(OH)D levels are associat-
ed with vascular endothelial dysfunction (proin-
flammatory endothelial activation and vasodilator 
function) even in asymptomatic lean individuals 
[26, 27], BW can be a confounding factor for in-
terpreting the impact of low vitamin D status on 
endothelial dysfunction in obesity. In previous 
studies with obese patients, BW and abnormal 
glucose metabolism were the main determinants 
of increased soluble adhesion molecule levels [9, 
25, 28]. In our study, additionally to sE-selectin 
levels, only BMI and 2hPG were significantly high-
er in obese patients with lower vitamin D levels. 
Moreover, sE-selectin was inversely associated 
with 25(OH)D levels in obese patients, suggesting 
that low vitamin D status may promote endotheli-
al dysfunction (proinflammatory endothelial acti-
vation/dysfunction) in obesity. Also, some studies 
have shown an inverse association between vita-
min D level and parameters of glucose metabo-
lism [20, 22], but our study did not demonstrate 
such a relationship.
Vitamin D insufficiency has been associated 
with higher endothelial activation and dysfunc-
tion [17]. According to some authors, vitamin D 
inadequacy in an adult, i.e. true insufficiency, ex-
ists when the level is < 37.5 nmol/l [33]. Precisely 
defining vitamin D insufficiency in obese subjects 
on the basis of serum 25(OH)D levels is still a mat-
ter of debate. Due to the lack of standardized cut-
off points for 25(OH)D insufficiency in our country, 
and considering that the majority of obese sub-
jects in general as in our study had a lower than 
optimal vitamin D serum level, we selected our 
analysis according to the median serum 25(OH)D 
nmol/l in the obese study group (i.e. 31 nmol/l). 
Additionally, according to the results of the first 
meta-analysis that assessed the association be-
tween obesity (i.e. different levels of BMI) and vi-
tamin D deficiency, the cut-offs used for vitamin D 
deficiency were ≤ 25, ≤ 35 or ≤ 50 nmol/l [34]. 
We observed a negative association between 
sICAM-1 and vitamin D levels in obese individ-
uals, but this association was not significant in 
multivariate analysis. The confounding effect of 
obesity could be a  reason for this finding, since 
in the Framingham Offspring Study for every 
5 kg/m2 increase in BMI, sICAM-1 levels were 
raised by 5 ng/ml [35]. Some studies have re-
ported that sICAM-1 levels may reflect its pro-
duction not only by ECs outside adipose tis-
sue, but also by adipocytes and macrophages 
within adipose tissue, thus creating a  proin-
flammatory state in obesity [36]. Experimen-
tal data indicate that treatment with vitamin D 
may regulate the expression of adhesion mole-
cules by decreasing ICAM-1 levels [37], though 
results from interventional studies are discordant 
regarding the potential effect of vitamin D sup-
plementation in reducing the levels of endothelial 
dysfunction markers in obese individuals [38, 39]. 
In addition to increased levels of endothelial 
dysfunction biomarkers, obese patients in our 
study had significantly higher hsCRP levels com-
pared with controls. Adipocytes, predominantly 
in the visceral compartment, may express and 
secrete proinflammatory cytokines, which induce 
a systemic acute-phase response via the produc-
tion of acute-phase reactants in hepatocytes and 
ECs. Thus, adipose tissue mass may be an import-
ant mediator in the interaction between obesity 
and inflammation [40]. Also in ECs, acute-phase 
reactants activate nuclear factor kB (NF-kB), 
a  proinflammatory transcription factor, which 
stimulates the production of proinflammatory cy-
tokines and the expression of adhesion molecules 
such as ICAM-1 and E-selectin [17]. In vitro stud-
ies suggest that vitamin D may exert immuno-
modulatory effects and decrease CRP levels [41]. 
In the present study, we found significantly lower 
hsCRP levels in obese patients with ≥ 31 nmol/l 
than those with 25(OH)D < 31 nmol/l as well as an 
inverse association between 25(OH)D and hsCRP 
levels in the obese group. Furthermore, multivar-
iate regression analysis suggesting an inverse 
association between hsCRP and sE-selectin with 
serum 25 (OH) D level could highlight the role of 
vitamin D bioavailability in the systemic and vas-
cular endothelial inflammatory response in obese 
individuals. hsCRP is regarded as a better marker 
of CVD than soluble adhesion molecules, cytokines 
and other acute-phase reactants [42]. It is also 
important to consider that vitamin D insufficiency 
may affect adherence to statin therapy [43]. 
This study has several limitations. It is a cross- 
sectional pilot study with a small number of pa-
tients, and we did not have any specific informa-
tion about sunlight exposure and dietary vita- 
min D. Comparisons with previous studies are lim-
ited by differences in population characteristics, 
vitamin D insufficiency cut-off points and assay 
methods.
In conclusion, adipose tissue and the endothe-
lium maintain vascular homeostasis. Vitamin D 
insufficiency associated with obesity may further 
promote the inflammatory status and endothelial 
dysfunction, significantly increasing CV risk. Both 
obesity and vitamin D insufficiency/deficiency are 
modifiable factors with high prevalence in sever-
al countries [18, 44]. Further trials are needed to 
establish the clinical implications of preventing, 
or at least adequately treating, these chronic car-
diometabolic abnormalities. 
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